CM
ADMS

Caption Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Caption Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-27,400
Closed -$103K – 1187
2019
Q4 		$103K Buy
+27,400
New +$131K ﹤0.01% 755

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caption Management's ADMS Position: Q1 2019 in Review

Caption Management sold out of Adamas Pharmaceuticals (ADMS) in Q1 2019, closing a stake of 55,000 shares — an estimated $470K sold.

Caption Management first reported a position in ADMS in Q3 2018 and held it in 2 quarters. The position peaked at $729K in Q3 2018. 99 funds tracked by Wall St. Rank hold ADMS as of Q1 2019.

  • Caption Management reported no remaining Adamas Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Caption Management sold 55,000 Adamas Pharmaceuticals shares in Q1 2019, an estimated $470K.
  • Caption Management first reported a position in Adamas Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Caption Management's Adamas Pharmaceuticals position peaked at $729K in Q3 2018.
  • 99 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2019.

Based on Caption Management's 13F filing for Q1 2019, filed 14 May 2019.